Abstract:Our previous studies have indicated that myoepithelial cells surrounding ductal and acinar epithelium of glandular organs, such as the breast, exert multiple paracrine suppressive effects on incipient and developing cancers that arise from this epithelium. Myoepithelial cells and derived cell lines (HMS 1–6) exert these effects through the secretion of a number of different effector molecules that exert anti-invasive, anti-proliferative, and anti-angiogenic activities. Since previous basic and clinical studies have examined the role of estrogen agonists and antagonists on human breast cancer cells and because issues of hormone replacement therapy (HRT) and tamoxifen chemoprevention are such timely issues in breast cancer, we wondered whether or not hormonal manipulations might affect myoepithelial cells in vitro as far as their paracrine suppressive activities on breast cancer were concerned. The present in vitro study demonstrates that treatment of myoepithelial cells with tamoxifen but not 17β-estradiol increases both maspin secretion and invasion-blocking ability. Furthermore tamoxifen but not 17β-estradiol increases inducible nitric oxide synthase (iNOS) expression and nitric oxide (NO) production by myoepithelial cells when they are co-cultured with conditioned media from or breast carcinoma cells directly. This increased myoepithelial NO exerts both autocrine and paracrine antiproliferative effects which can be blocked by inhibition of iNOS. 17β-Estradiol, however, competes with all of these suppressive effects of tamoxifen suggesting that the mechanism of tamoxifen action is estrogen receptor mediated. Myoepithelial cells lack ER-α but express ER-β. Tamoxifen, but not 17β-estradiol, increases AP-1 CAT but not ERE-CAT activity. Again, 17β-estradiol competes with the transcription-activating effects of tamoxifen. These experiments collectively suggest that the actions of tamoxifen on the increased secretion of maspin and increased production of NO by myoepithelial cells are mediated through ER-β and the transcription-activation of an ER-dependent AP-1 response element.

Effects of Tamoxifen on DNA Adduct Formation and Arylamines N-acetyltransferase Activity in Human Breast Cancer Cells.

Advances in mechanism of tamoxifen resistance in estrogen receptor-positive breast cancer

[A Study on the Effect of Tanshinone II A Against Human Breast Cancer in Vivo].

[A Study on Anticancer Activity of Tanshinone II A Against Human Breast Cancer].

DNA adduct formation by tamoxifen and structurally-related compounds in rat liver

N-acetyltransferase Activity and 2-Aminofluorene-dna Adducts Formation in Human Colon Cancer

Tamoxifen induced changes in MCF7 human breast cancer: in vitro and in vivo studies using nuclear magnetic resonance spectroscopy and imaging

Tamoxifen Enhances Myoepithelial Cell Suppression of Human Breast Carcinoma Progression in Vitro by Two Different Effector Mechanisms

Elimination of Antiestrogenic Effects of Active Tamoxifen Metabolites by Glucuronidation.

Effects of Estradiol and Tamoxifen on Proliferation of Human Breast Cancer Cells and Human Endometrial Cells.

Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue

[Effect of Mitogen-Activated Protein Kinase Signal Transduction in Non-Estrogen Antagonistic Mechanism of Tamoxifen].

Effects of Butylated Hydroxyanisole and Butylated Hydroxytoluene on Dna Adduct Formation and Arylamine N‐acetyltransferase Activity in Human Bladder Tumour Cells

Paclitaxel Inhibits N-acetyltransferase Activity and Gene Expression in Human Stomach Tumor Cells (SC-M1).

The effect of tamoxifen as an adjuvant therapy for breast cancer on apolipoproteins and lipoprotein(a) concentrations in women: A meta-analysis of randomized controlled trials

Novel Tumor-Promoting Property of Tamoxifen

Tamoxifen induces radioresistance through NRF2-mediated metabolic reprogramming in breast cancer

Dose-dependent effect of tamoxifen in tamoxifen-resistant breast cancer cells via stimulation by the ERK1/2 and AKT signaling pathways.

The Synergistic Inhibitory Effect of 5-Aza-2-deoxycytidine and Tamoxifen on Estrogen Receptor Alpha Negative Breast Cancer Cell Lines in Vitro

Preliminary Results of Postoperative Adjuvant Treatment with Tamoxifen in Colorectal Cancer

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine